Immunological Monitoring During Anti-CD20 Therapies to Predict Infection Risk and Treatment Response in Multiple Sclerosis Patients
Baseline immunophenotype and immunological monitoring can help predict the risk of infections and the efficacy of anti-CD20 therapy in MS patients.
Authors
- Ana Martínez‐Feito (ORCID: https://orcid.org/0000-0002-5580-8387)
- Inmaculada Puertas (ORCID: https://orcid.org/0000-0002-9567-1274)
- Andrea González‐Torbay (ORCID: https://orcid.org/0000-0002-1481-0018)
- Claudia Geraldine Rita (ORCID: https://orcid.org/0000-0003-2103-0973)
- Beatriz Chamorro
- Gabriel Torres Iglesias (ORCID: https://orcid.org/0000-0001-6479-731X)
- Mireya Fernández-Fournier (ORCID: https://orcid.org/0000-0002-4885-0181)
- Laura Otero‐Ortega (ORCID: https://orcid.org/0000-0001-8765-6341)
- MariPaz López-Molina (ORCID: https://orcid.org/0000-0002-9171-2606)
- Eduardo López‐Granados (ORCID: https://orcid.org/0000-0002-3646-3870)
- Exuperio Díez-Tejedor
- Sara Sánchez Velasco
Institutions
- Hospital Universitario La Paz (ES)
- Hospital La Paz Institute for Health Research (ES)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Diseases
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3390/diseases13120387
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00